Smartlens

Smartlens is a clinical-stage Med Tech company focused on developing innovative technologies for diagnosing and treating glaucoma, a leading cause of irreversible blindness. Its primary product, miLens, is a microfluidic-based smart contact lens designed for continuous monitoring of intraocular pressure (IOP), addressing the urgent need for home-based monitoring solutions. Current clinical trials indicate that miLens offers an accurate alternative to traditional office-based devices, potentially enhancing early diagnosis and personalized treatment for patients. The technology is non-invasive and utilizes a unique electronics-free sensor, which is supported by a robust portfolio of patents across multiple countries. In addition to its core focus on glaucoma, Smartlens is exploring applications for its technology in monitoring intracranial pressure, associated with neurological disorders and cancers, in collaboration with Stanford University Labs. The company has been recognized for its innovative contributions to medical technology and has gained visibility through various media outlets and industry conferences. Smartlens aims to improve patient outcomes, reduce treatment costs, and mitigate the societal impact of blindness through its cutting-edge solutions.